Locus Biosciences
A biotechnology company that develops CRISPR-engineered precision antibacterial products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $23.9m | Grant | |
| Total Funding | 000k | ||
Related Content
Locus Biosciences operates in the biotechnology sector, focusing on the development of precision antibacterial products to treat infectious diseases and microbiome-related conditions. The company leverages CRISPR-Cas3 engineered bacteriophages, branded as crPhage™, to specifically target and eradicate harmful bacterial pathogens. Locus Biosciences serves clients in the healthcare and pharmaceutical industries, including partnerships with major pharmaceutical companies like Janssen Pharmaceuticals. The company operates in the global market, with a business model centered around the development, licensing, and commercialization of its proprietary technologies. Revenue is generated through licensing agreements, research collaborations, and potential future sales of approved therapeutic products.
Keywords: CRISPR, bacteriophage, infectious diseases, microbiome, biotechnology, precision medicine, healthcare, pharmaceuticals, licensing, commercialization.